Pharmacokinetic parameters of dynamic contrast enhanced MRI in differential diagnosis of primary central nervous system lymphoma and glioblastoma
10.13929/j.1003-3289.201701111
- VernacularTitle:动态对比增强MRI衍生的药代动力学参数鉴别诊断原发性中枢神经系统淋巴瘤与胶质母细胞瘤
- Author:
Yu ZHANG
1
;
Qian ZHANG
;
Xiangwei LUO
;
Xuefei DENG
;
Youzhi ZHU
Author Information
1. 中国人民解放军第105医院医学影像科
- Keywords:
Central nervous system;
Lymphoma;
Glioblastoma;
Magnetic resonance imaging;
Pharmacokinetics
- From:Chinese Journal of Medical Imaging Technology
2017;33(11):1630-1635
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the difference of pharmacokinetic parameters derived from dynamic contrast enhanced (DCE) MRI between primary central nervous system lymphoma (PCNSL) and glioblastoma (GBM).Methods Data of 17 patients with PCNSL and 21 patients with GBM were retrospectively analyzed.All patients underwent DCE MRI.The pharmacokinetic parameters (K,Kep,Ve) and the initial (60 s) area under the Gd concentration-time curve (iAUC) of peri-tumoral parenchymas (PT),enhancement tumors (ET) and contralateral normal parenchyma (NP) were obtained.The differences of various parameters were compared among different regions of PCNSL and GBM using one-way ANOVA.The differences of various parameters of PT,ET and NP were compared using independent samples t-test.Results There were statistical differences of K,Kep in ET,Kep in PT between PCNSL and GBM patients (all P＜0.05),as well as of K,Kep,Ve,iAUC in PCNSL and GBM patients between ET and PT (all P＜0.05).However,K and Kepof PT showed statistical differences compared with those of NP in GBM patients (both P＜0.05),so did Ktrans between PT and NP in PCSL patients (P＜0.05).Conclusion The pharmacokinetic parameters derived from DCE MRI based on extended Tofts Linear can promote differential diagnosis between PCNSL and GBM.
